Biochemical markers of inflammation are associated with increased mortality in hip fracture patients: the Bispebjerg Hip Fracture Biobank

  • Debbie Norring-AgerskovEmail author
  • Lise Bathum
  • Ole B. Pedersen
  • Bo Abrahamsen
  • Jes B. Lauritzen
  • Niklas R. Jørgensen
  • Henrik L. Jørgensen
Original Article



The purpose of this study was to examine the possible association between mortality following a hip fracture and known biochemical markers of inflammation.


The study population was identified using two local databases from Bispebjerg Hospital (Copenhagen, Denmark): the Hip Fracture Database containing all patients admitted to the hospital with a fractured hip from 1996 to 2012 and the Hip Fracture Biobank, containing whole blood, serum and plasma taken in relation to admission on a subgroup of patients from the Hip Fracture Database, consecutively collected over a period of 2.5 years from 2008 to 2011. The following biochemical markers of inflammation were included: C-reactive protein (CRP), the soluble urokinase plasminogen activating receptor (suPAR), ferritin and transferrin. The association between the blood markers and mortality was examined using Cox proportional hazards models. Hazard ratios (HR) were expressed per quartile increase in the biochemical markers.


A total of 698 patients were included, 69 (9.9%) died within 30 days after sustaining a hip fracture. The HR for 30-day mortality was significantly increased with increasing quartiles of suPAR, CRP and ferritin and with decreasing quartiles of transferrin.


This study shows that 30-day mortality after a hip fracture is associated with elevated levels of suPAR, CRP and ferritin as well as with lower levels of transferrin. This excess inflammatory response is likely caused by muscle damage associated with the hip fracture. However, this needs to be further clarified.


Hip fracture Mortality Inflammatory markers Prognosis 


Author contributions

All authors have contributed significantly to the manuscript. Study design: all authors. Processing and preparation of raw data for subsequent analyses: BA, HLJ. Preparation of biobank material: DNA. Data analysis: DNA, HLJ. Interpretation of data: all authors. Drafting of the manuscript: DNA. Critical review of the manuscript for intellectual content and approval of final version: all authors. Guarantor: DNA.


This research was supported by a Grant from Region Zealand.

Compliance with ethical standards

Conflict of interest

Debbie Norring-Agerskov, Lise Bathum, Ole B. Pedersen, Bo Abrahamsen, Jes B. Lauritzen, Niklas R. Jørgensen, and Henrik L. Jørgensen declare that they have no conflict of interest.

Statement of human and animal rights

The human data are derived from registers and the data were anonymized prior to our use. Animals were not used in this study.

Informed consent

In this case, informed consent from the individual patients is not required according to Danish law.


  1. 1.
    Abrahamsen B, van Staa T, Ariely R et al (2009) Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 20:1633–1650CrossRefGoogle Scholar
  2. 2.
    Hernlund E, Svedbom A, Ivergård M et al (2013) Osteoporosis in the European Union: Medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:1–2CrossRefGoogle Scholar
  3. 3.
    Kannegaard PN, van der Mark S, Eiken P et al (2010) Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing 39:203–209CrossRefGoogle Scholar
  4. 4.
    Norring-Agerskov D, Laulund AS, Lauritzen JB et al (2013) Metaanalysis of risk factors for mortality in patients with hip fracture. Dan Med J 60:A4675Google Scholar
  5. 5.
    Daugaard CL, Jorgensen HL, Riis T et al (2012) Is mortality after hip fracture associated with surgical delay or admission during weekends and public holidays? A retrospective study of 38,020 patients. Acta Orthop 83:609–613CrossRefGoogle Scholar
  6. 6.
    Laulund AS, Lauritzen JB, Duus BR et al (2012) Routine blood tests as predictors of mortality in hip fracture patients. Injury 43:1014–1020CrossRefGoogle Scholar
  7. 7.
    Norring-Agerskov D, Madsen CM, Abrahamsen B et al (2017) Hyperkalemia is Associated with Increased 30-Day Mortality in Hip Fracture Patients. Calcif Tissue Int 101:9–16CrossRefGoogle Scholar
  8. 8.
    Madsen CM, Jantzen C, Lauritzen JB et al (2015) Hyponatremia and hypernatremia are associated with increased 30-day mortality in hip fracture patients. Osteoporos Int 27:297–404Google Scholar
  9. 9.
    Mosfeldt M, Pedersen OB, Riis T et al (2012) Value of routine blood tests for prediction of mortality risk in hip fracture patients. Acta Orthop 83:31–35CrossRefGoogle Scholar
  10. 10.
    Kim BG, Lee YK, Park HP et al (2016) C-reactive protein is an independent predictor for 1-year mortality in elderly patients undergoing hip fracture surgery: a retrospective analysis. Medicine (Baltimore) 95:e5152CrossRefGoogle Scholar
  11. 11.
    Fakler JK, Grafe A, Dinger J et al (2016) Perioperative risk factors in patients with a femoral neck fracture—influence of 25-hydroxyvitamin D and C-reactive protein on postoperative medical complications and 1-year mortality. BMC Musculoskelet Disord 17:51CrossRefGoogle Scholar
  12. 12.
    Sun T, Wang X, Liu Z et al (2011) Plasma concentrations of pro- and anti-inflammatory cytokines and outcome prediction in elderly hip fracture patients. Injury 42:707–713CrossRefGoogle Scholar
  13. 13.
    Forasassi C, Golmard JL, Pautas E et al (2009) Inflammation and disability as risk factors for mortality in elderly acute care patients. Arch Gerontol Geriatr 48:406–410CrossRefGoogle Scholar
  14. 14.
    Kompoti M, Drimis S, Papadaki A et al (2008) Serum C-reactive protein at admission predicts in-hospital mortality in medical patients. Eur J Intern Med 19:261–265CrossRefGoogle Scholar
  15. 15.
    Rallidis LS, Vikelis M, Panagiotakos DB et al (2006) Inflammatory markers and in-hospital mortality in acute ischaemic stroke. Atherosclerosis 189:193–197CrossRefGoogle Scholar
  16. 16.
    Winbeck K, Poppert H, Etgen T et al (2002) Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 33:2459–2464CrossRefGoogle Scholar
  17. 17.
    Liuzzo G, Biasucci LM, Gallimore JR et al (1994) The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331:417–424CrossRefGoogle Scholar
  18. 18.
    Avram MM, Fein PA, Paluch MM et al (2005) Association between C-reactive protein and clinical outcomes in peritoneal dialysis patients. Adv Perit Dial 21:154–158Google Scholar
  19. 19.
    Ritchie RF, Palomaki GE, Neveux LM et al (1999)Reference distributions for the negative acute-phase proteins, albumin, transferrin, and transthyretin: a comparison of a large cohort to the world’s literature. J Clin Lab Anal 13:280–286CrossRefGoogle Scholar
  20. 20.
    Ebersole JL, Cappelli D (2000) Acute-phase reactants in infections and inflammatory diseases. Periodontol 23:19–49CrossRefGoogle Scholar
  21. 21.
    Haupt TH, Kallemose T, Ladelund S et al (2014) Risk factors associated with serum levels of the Inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population. Biomark Insight 9:91–100CrossRefGoogle Scholar
  22. 22.
    Eugen-Olsen J, Andersen O, Linneberg A et al (2010) Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 268:296–308CrossRefGoogle Scholar
  23. 23.
    Helweg-Larsen K (2011) The Danish Register of Causes of Death. Scand J Public Health 39:26–29CrossRefGoogle Scholar
  24. 24.
    Lynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public Health 39:30–33CrossRefGoogle Scholar
  25. 25.
    Pedersen CB (2011) The Danish Civil Registration System. Scand J Public Health 39:22–25CrossRefGoogle Scholar
  26. 26.
    Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefGoogle Scholar
  27. 27.
    Petersen MB, Jørgensen HL, Hansen K et al (2006) Factors affecting postoperative mortality of patients with displaced femoral neck fracture. Injury 37:705–711CrossRefGoogle Scholar
  28. 28.
    Agarwal N, Prchal JT (2009) Anemia of chronic disease (Anemia of Inflammation). Acta Haematol 122:103–108CrossRefGoogle Scholar
  29. 29.
    Giannoglou GD, Chatzizisis YS, Misirli G (2007) The syndrome of rhabdomyolysis: pathophysiology and diagnosis. Eur J Intern Med 18:90–100CrossRefGoogle Scholar
  30. 30.
    Sedlář M, Kvasnička J, Krška Z et al (2015) Early and subacute inflammatory response and long-term survival after hip trauma and surgery. Arch Gerontol Geriatr 60:431–436CrossRefGoogle Scholar
  31. 31.
    Beloosesky Y, Grinblat J, Pirotsky A et al (2004) Different C-reactive protein kinetics in post-operative hip-fractured geriatric patients with and without complications. Gerontology 50:216–222CrossRefGoogle Scholar
  32. 32.
    Gonzalez-Montalvo JI, Alarcon T, Mauleon JL et al (2010) The orthogeriatric unit for acute patients: a new model of care that improves efficiency in the management of patients with hip fracture. Hip Int 20:229–235CrossRefGoogle Scholar
  33. 33.
    Adunsky A, Lusky A, Arad M et al (2003) A comparative study of rehabilitation outcomes of elderly hip fracture patients: the advantage of a comprehensive orthogeriatric approach. J Gerontol A Biol Sci Med Sci 58:542–547CrossRefGoogle Scholar
  34. 34.
    Pedersen SJ, Borgbjerg FM, Schousboe B et al (2008) A comprehensive hip fracture program reduces complication rates and mortality. J Am Geriatr Soc 56:1831–1838CrossRefGoogle Scholar
  35. 35.
    Stenqvist C, Madsen CM, Riis T et al (2016) Orthogeriatric service reduces mortality in patients with hip fracture. Geriatr Orthop Surg Rehabil 7:67–73CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Clinical BiochemistryHvidovre HospitalHvidovreDenmark
  2. 2.Department of Orthopedic SurgeryBispebjerg HospitalCopenhagen NVDenmark
  3. 3.Department of Clinical ImmunologyNæstved SygehusNæstvedDenmark
  4. 4.Department of MedicineHolbæk HospitalHolbækDenmark
  5. 5.Department of Clinical BiochemistryRigshospitalet GlostrupGlostrupDenmark
  6. 6.Odense Patient Data Explorative NetworkUniversity of Southern Denmark and Odense University HospitalOdense CDenmark
  7. 7.Department of Clinical MedicineUniversity of CopenhagenCopenhagen NDenmark

Personalised recommendations